Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8893652 | 0.80 | TAAR1 (0.65) | PNMTTAAR1CYP3A4MAPK1 | |
| SCHEMBL671453 | 0.80 | PNMT (0.54) | PNMTTAAR1DPP4IDO1CYP3A4 | |
| SCHEMBL16300075 | 0.80 | PNMT (0.54) | PNMTTAAR1DPP4IDO1CYP3A4 | |
| SCHEMBL42705 | 0.79 | PNMT (1.00) | PNMTTAAR1DPP4IDO1 | |
| SCHEMBL22855023 | 0.78 | PNMT (0.52) | PNMTTAAR1DPP4IDO1 | |
| SCHEMBL30139647 | 0.78 | PNMT (0.58) | PNMTTAAR1DPP4IDO1 | |
| SCHEMBL4465598 | 0.78 | CYP3A4 (0.43) | PNMTTAAR1IDO1CYP3A4MAPK1 | |
| Hydrochloric Acid SCHEMBL9035217 | 0.77 | PNMT (0.95) | PNMTTAAR1DPP4IDO1CYP3A4 | |
| SCHEMBL3727971 | 0.76 | CYP3A4 (0.42) | PNMTTAAR1IDO1CYP3A4MAPK1 | |
| SCHEMBL22469536 | 0.75 | PNMT (0.48) | PNMTTAAR1DPP4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | PNMT 3431/4885TAAR1 163/4885DPP4 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.